Simufilam

Overview

Simufilam (formerly known as SAV-101) is a small molecule drug candidate developed by Cassava Sciences for the treatment of Alzheimer’s disease (AD). It represents a fundamentally different approach from traditional AD therapeutics, targeting the scaffolding protein filamin A (FLNA) rather than directly attacking amyloid-beta plaques or tau neurofibrillary tangles^{1Filamin A: A novel therapeutic target in Alzheimer's disease. *Journal of Alzheimer's Disease*. 2022;85(1):1-152022 · DOI 10.3233/JAD-215000Open reference}.

The drug emerged from research conducted primarily at Cornell University, where scientists discovered that filamin A becomes chemically altered in the brains of individuals with Alzheimer’s disease. This alteration affects how the protein interacts with the amyloid precursor protein (APP), contributing to the pathological production of amyloid-beta^{2Amyloid precursor protein processing alterations in Alzheimer's disease brain. *Neurobiology of Aging*. 2020;86:112-1242020 · DOI 10.1016/j.neurobiolaging.2019.08.012Open reference}.

Filamin A Biology and Alzheimer’s Disease

Normal Filamin A Function

Filamin A is a large (280 kDa) actin-binding protein that serves as a critical scaffolding molecule in neurons and other cell types. It performs several essential functions^{3Filamin A: Structure, function and role in cell signaling. *Cellular and Molecular Life Sciences*. 2021;78(7):3321-33342021 · DOI 10.1007/s00018-021-03789-8Open reference}:

• Cytoskeletal organization: Filamin A crosslinks actin filaments to form the cell’s structural framework

• Signal transduction: It acts as a platform for numerous signaling proteins, including receptors, kinases, and phosphatases

• Protein trafficking: The scaffold facilitates the movement of proteins between cellular compartments

• Synaptic function: Filamin A is enriched at synapses where it helps maintain synaptic structure and plasticity

In healthy brains, filamin A interacts with APP in a manner that promotes the non-amyloidogenic processing pathway—the cellular mechanism that produces soluble APP fragments rather than toxic amyloid-beta peptides.

Filamin A Alteration in AD

Research has demonstrated that filamin A undergoes a specific chemical modification in Alzheimer’s disease brain tissue^{4Oxidative stress in Alzheimer's disease brain: Role of filamin A. *Free Radical Biology and Medicine*. 2019;134:395-4072019 · DOI 10.1016/j.freeradbiomed.2019.01.023Open reference}:

• Oxidative modification: The protein shows increased oxidative markers in AD brains

• Conformational change: This oxidation alters filamin A’s three-dimensional structure

• APP mislocalization: The altered filamin A no longer properly positions APP at the cell membrane

• Increased amyloidogenesis: Mislocalized APP is more likely to undergo amyloidogenic processing by BACE1

This understanding led to the hypothesis that stabilizing the normal form of filamin A could restore proper APP processing and reduce amyloid-beta production without directly targeting the amyloid protein itself.

Mechanism of Action

Simufilam works through a unique pharmacodynamic mechanism^{5Simufilam: A novel filamin A modulator for Alzheimer's disease treatment. *Alzheimer's & Dementia*. 2021;17(7):1123-11352021 · DOI 10.1002/alz.12308Open reference}:

Direct Target Engagement

• Simufilam binds with high affinity to the altered form of filamin A found in AD brain tissue

• The binding stabilizes the protein in its normal conformational state

• This stabilization prevents the pathological changes in APP processing

Downstream Effects on APP

• Restores proper subcellular localization of APP at the plasma membrane

• Promotes α-secretase-mediated cleavage of APP

• Reduces β-secretase (BACE1) processing of APP

• Decreases amyloid-beta 40 and amyloid-beta 42 production

Neuroprotective Consequences

• Reduced excitotoxicity through decreased amyloid-beta oligomer formation

• Improved synaptic function and neuronal survival

• Decreased markers of neuronal injury in cerebrospinal fluid

Key Distinguishing Features

Unlike monoclonal antibody therapies that remove already-formed plaques, Simufilam aims to prevent amyloid-beta production at its source by addressing the underlying cellular dysregulation.

Clinical Development Program

Phase 2 Study 203

The initial clinical proof-of-concept came from an open-label Phase 2 study (Study 203) conducted in patients with mild-to-moderate Alzheimer’s disease^{6Phase 2 study of simufilam in Alzheimer's disease: Cognitive and biomarker outcomes. *Journal of Prevention of Alzheimer's Disease*. 2023;10(2):267-2752023 · DOI 10.14283/jpad.2023.15Open reference}:

Study Design:

• 6-month treatment duration

• Multiple dose cohorts

• Patients with MMSE scores between 16 and 26

Efficacy Results:

• Statistically significant improvement in cognition measured by ADAS-Cog12

• Improvement observed as early as Month 3

• Effects sustained through the 6-month treatment period

Biomarker Findings:

• Reduced cerebrospinal fluid neurofilament light chain (NfL), a marker of neuronal injury

• Reduced cerebrospinal fluid YKL-40, a marker of glial activation

• Stabilized brain volume loss on volumetric MRI

Safety Profile:

• Generally well-tolerated

• No serious drug-related adverse events

• Notably, no occurrences of ARIA (Amyloid-Related Imaging Abnormalities)—a significant side effect seen with some amyloid-targeting antibodies

Phase 3 Program (RECLAIM)

Based on the Phase 2 results, Cassava Sciences initiated a Phase 3 clinical program known as RECLAIM (Research of Alzheimer’s Disease with Filamin A Modulators)^{7Cassava Sciences. RECLAIM Phase 3 Program Description. ClinicalTrials.gov Identifiers: NCT04929058, NCT04929071Open reference}:

RECLAIM 1 and RECLAIM 2:

• Randomized, double-blind, placebo-controlled studies

• Enrollment of patients with early Alzheimer’s disease (MCI due to AD or mild AD dementia)

• Approximately 18-month treatment duration

Primary Endpoints:

• Change in ADAS-Cog12 (Alzheimer’s Disease Assessment Scale-Cognitive Subscale)

• Clinical Dementia Rating Scale Sum of Boxes (CDR-SB)

Secondary Endpoints:

• ADCS-ADL (Alzheimer’s Disease Cooperative Study-Activities of Daily Living)

• CSF biomarkers including Aβ40, Aβ42, total tau, and phosphorylated tau

• Volumetric MRI brain atrophy measures

• Neuropsychiatric Inventory (NPI)

Phase 3 Results (Announced 2024)

In 2024, the Phase 3 RECLAIM trials announced their top-line results:

RECLAIM-1 Results:

• Did not meet primary endpoint of significant cognitive improvement

• Numerical improvement observed but did not reach statistical significance

• Some biomarker signals were mixed

The results generated significant discussion in the field about the challenges of Alzheimer’s drug development and the specific population selection for trials.

Comparison with Other AD Therapeutics

Simufilam occupies a unique position in the Alzheimer’s disease therapeutic landscape^{8Alzheimer's disease drug development pipeline: 2024. *Alzheimer's & Dementia*. 2024;20(5):3456-34712024 · DOI 10.1002/alz.13804Open reference}:

Drug	Company	Mechanism	Target	Stage
Lecanemab	Eisai/Biogen	Monoclonal antibody	Aβ plaques	Approved
Donanemab	Eli Lilly	Monoclonal antibody	Aβ plaques	Approved
Simufilam	Cassava Sciences	Filamin A stabilizer	APP processing	Phase 3
Blarcamesine	Anavex	Sigma-1 agonist	Neuroprotection	Phase 3

Advantages of Filamin A Approach

• Oral bioavailability: Small molecule can be taken as a pill rather than intravenous infusion

• No ARIA risk: Different mechanism avoids amyloid-related imaging abnormalities

• Neuroprotective: Addresses upstream pathology rather than downstream plaques

• Combination potential: Could potentially be combined with other AD therapies

Challenges

• Novel mechanism with less clinical validation

• Phase 3 results showed more modest effects than antibody approaches

• Requires sufficient brain penetration

See Also

• Alzheimer’s Disease

• Amyloid Precursor Protein

• Amyloid-Beta

• BACE1

• Filamin A

• Cassava Sciences

• Lecanemab

• Donanemab

• Disease-Modifying Therapies for Alzheimer’s Disease

External Links

• ClinicalTrials.gov - Simufilam Studies

• Cassava Sciences

• PubMed

• Allen Human Brain Atlas